Comparison
Selank vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
129954-34-3
2179963-22-7
Molecular weight
751.85 g/mol
4727 g/mol
Half-life
0.3 h
168 h
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Promodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
2
of which in humans
2
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2